According to filings with the U.S. Securities and Exchange Commission, Perspective Therapeutics is raising $54,618,030.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Johan Spoor played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Perspective Therapeutics
At Perspective Therapeutics we’ve combined the best of two great companies – Isoray and Viewpoint Molecular Targeting. Together, with over a quarter century in the medical technologies market, we continue progressing down a path of focused innovation with the patient at the center of our business. Our focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so our targeted medical doses are delivered directly to the tumor site. We believe radiation should spare healthy tissues and be delivered from the inside out. We are committed to identifying ways to best deliver therapies for patients and their medical needs and believe in a targeted personalized approach to treating each patients cancer. We develop treatments that are delivered exactly where the surgeon wants them delivered. Our partnerships and trials with globally recognized medical institutions and pharmaceutical companies are reflective of our goal to be at the forefront of progress and innovation. All of this is grounded in our continual pursuit of meeting and exceeding patient needs. .

To learn more about Perspective Therapeutics, visit http://perspectivetherapeutics.com/

Contact:
Johan Spoor, Chief Executive Officer
509-375-1202

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.